Monitoring of nuclear factor of activated t-cell-regulated gene expression in de novo and long-term liver transplant recipients treated with cyclosporine A

Therapeutic Drug Monitoring

Volumn 33, Issue 2, 2011, Pages 185-191

  Herden, Uta ^a   Kromminga, Arno ^a,b   Hagel, Christine ^b   Hartleb, Jürgen ^b   Nashan, Björn ^a   Sterneck, Martina ^a   Fischer, Lutz ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b Labor Lademannbogen   (Germany)

Author keywords

immunosuppression; liver transplantation; NFAT regulated gene expression; therapeutic drug monitoring

Indexed keywords

BASILIXIMAB; CYCLOSPORIN A; EVEROLIMUS; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; STEROID;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DRUG DOSE REDUCTION; DRUG EFFECT; FEMALE; GENE EXPRESSION; GRAFT RECIPIENT; HUMAN; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

CYCLOSPORINE; DRUG MONITORING; GENE EXPRESSION; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-GAMMA; INTERLEUKIN-2; LIVER TRANSPLANTATION; LYMPHOCYTES; NFATC TRANSCRIPTION FACTORS; T-LYMPHOCYTES; TIME FACTORS;

EID: 79953168015     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e318210e6d0     Document Type: Article

References (20)

1. Hariharan S, Johnson CP, Bresnahan BA, et al. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med. 2000;342:605-612. (Pubitemid 30118412)
2. Ready A. Experience with cyclosporine. Transplant Proc. 2004;36: 135S-138S. (Pubitemid 38373847)
3. Howard RJ, Patton PR, Reed AI, et al. The changing causes of graft loss and death after kidney transplantation. Transplantation. 2002;73: 1923-1928. (Pubitemid 34701001)
4. Giese T, Sommerer C, Zeier M, et al. Monitoring immunosuppression with measures of NFAT decreases cancer incidence. Clin Immunol. 2009; 132:305-311.
5. Barama A, Sepandj F, Gough J, et al. Correlation between Neoral 2 hours post-dose levels and histologic findings on surveillance biopsies. Transplant Proc. 2004;36:465S-467S. (Pubitemid 38373913)
6. Grant D, Kneteman N, Tchervenkov J, et al. Peak cyclosporine levels (Cmax) correlate with freedom from liver graft rejection: results of a prospective, randomized comparison of Neoral and Sandimmune for liver transplantation (NOF-8). Transplantation. 1999;67:1133-1137. (Pubitemid 29205575)
7. Pescovitz MD, Barbeito R. Two-hour post-dose cyclosporine level is a better predictor than trough level of acute rejection of renal allografts. Clin Transplant. 2002;16:378-382.
8. Kasiske BL, Heim-Duthoy K, Rao KV, et al. The relationship between cyclosporine pharmacokinetic parameters and subsequent acute rejection in renal transplant recipients. Transplantation. 1988;46:716-722. (Pubitemid 19017047)
9. Internation Neoral Renal Transplantation Study Group. Randomized, international study of cyclosporine microemulsion absorption profiling in renal transplantation with basiliximab immunoprophylaxis. Am J Transplant. 2002;2:157-166.
10. Keown PA. New concepts in cyclosporine monitoring. Curr Opin Nephrol Hypertens. 2002;11:619-626. (Pubitemid 35440843)
11. Schiff J, Cole E, Cantarovich M. Therapeutic monitoring of calcineurin inhibitors for the nephrologist. Clin J Am Soc Nephrol. 2007;2:374-384.
12. Clipstone NA, Crabtree GR. Identification of calcineurin as a key signalling enzyme in T-lymphocyte activation. Nature. 1992;357: 695-697.
13. De Boer ML, Mordvinov VA, Thomas MA, et al. Role of nuclear factor of activated T cells (NFAT) in the expression of interleukin-5 and other cytokines involved in the regulation of hemopoetic cells. Int J Biochem Cell Biol. 1999;31:1221-1236. (Pubitemid 29454556)
14. Giese T, Zeier M, Schemmer P, et al. Monitoring of NFAT-regulated gene expression in the peripheral blood of allograft recipients: a novel perspective toward individually optimized drug doses of cyclosporine A. Transplantation. 2004;77:339-344. (Pubitemid 38209728)
15. Sommerer C, Giese T, Schmidt J, et al. Ciclosporin A tapering monitored by NFAT-regulated gene expression: a new concept of individual immunosuppression. Transplantation. 2008;85:15-21.
16. Sommerer C, Konstandin M, Dengler T, et al. Pharmacodynamic monitoring of cyclosporine a in renal allograft recipients shows a quantitative relationship between immunosuppression and the occurrence of recurrent infections and malignancies. Transplantation. 2006;82: 1280-1285. (Pubitemid 44832909)
17. Giese T, Zeier M, Meuer S. Analysis of NFAT-regulated gene expression in vivo: a novel perspective for optimal individualized doses of calcineurin inhibitors. Nephrol Dial Transplant. 2004; 19(Suppl 4):iv55-60. (Pubitemid 39136707)
18. Konstandin MH, Sommerer C, Doesch A, et al. Pharmacodynamic cyclosporine A-monitoring: relation of gene expression in lymphocytes to cyclosporine blood levels in cardiac allograft recipients. Transpl Int. 2007; 20:1036-1043. (Pubitemid 350043847)
19. Sommerer C, Hartschuh W, Enk A, et al. Pharmacodynamic immune monitoring of NFAT-regulated genes predicts skin cancer in elderly longterm renal transplant recipients. Clin Transplant. 2008;22:549-554.
20. John U, Ullrich S, Roskos M, et al. Two-hour postdose concentration: a reliable marker for cyclosporine exposure in adolescents with stable renal transplants. Transplant Proc. 2005;37:1608-1611. (Pubitemid 40712130)